- Acquired by Microbot Medical, May 2018
- Raised funding round, Jul 2014
- Raised funding round led by Maayan Ventures, Jun 2012
About
CardioSert develops tools designed to support interventional cardiologists in percutaneous coronary intervention (PCI) procedures. The companys products include a proprietary guide wire designed for crossing complex lesions, such as chronic total occlusion (CTO), and a pressure guide wire for measuring fractional flow reserve (FFR). CardioSerts CTO tool enables the physician to gently maneuver within the microchannels that pass throughout the arterial blockage. The tool follows the microchannels in order to pass the blockage safely and quickly, allowing the delivery of balloon/stent catheters to the desired location within the blockage. The companys FFR tool acts as an off-the-shelf workhorse guide wire and is equipped with a means for sensing the level of artery recanalization or assessing the level of artery blockage pre-operation, providing the physician with an important clinical decision-making tool. CardioSerts CTO tool was licensed by Microbot Medical Inc in 2018. In May 2019, Microbot acquired a novel patent-protected technology from CardioSert and now owns CardioSerts innovative technology, including R&D information, technical know-how, and intellectual property.
Funding history · 2 rounds · — total
Q&A
- What is CardioSert's primary business?
- CardioSert develops advanced tools for interventional cardiologists performing PCI procedures, including a proprietary guide wire for crossing complex lesions and a pressure guide wire for measuring fractional flow reserve (FFR).
- When was CardioSert founded?
- CardioSert was founded in March 2012.
- What is the current status of CardioSert?
- CardioSert was acquired by Microbot Medical in May 2018.
- Who were the lead investors in CardioSert's June 2012 funding round?
- Maayan Ventures was the lead investor in CardioSert's June 2012 funding round.
- Which investors participated in CardioSert's July 2014 funding round?
- Magna Capital Partners and Medvest participated in CardioSert's July 2014 funding round.
- How many employees does CardioSert have?
- CardioSert has 1-10 employees.
- Who are the co-founders of CardioSert?
- The co-founders of CardioSert are Avrahan Shkalim, who serves as CEO, and Noam Peleg, who serves as CTO.
- What happened to CardioSert's technology after the acquisition?
- In May 2019, Microbot Medical acquired a novel patent-protected technology from CardioSert, and now owns CardioSert's innovative technology, including R&D information, technical know-how, and intellectual property.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cardiosert.com/ |
|---|
Identifiers & details
| Founded | 2012-3 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Acquired by Microbot Medical on May, 2018 |
Acquisitions & public offerings
Acquired by Microbot Medical 2018-05
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | cardiosert.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|